



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, *Maeg* Washington, D. C. 20231 on March 16, 1999.

TOWNSEND and TOWNSEND and CREW LLP

By *Arlene C. Marshall*

Patent

Attorney Docket No. 13952A-005321

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of )

Andrzej Z. Sledziewski et al. )

Serial No. 08/980,400 )

Filed: November 26, 1997 )

For: METHODS OF PRODUCING )

SECRETED RECEPTOR )

ANALOGS AND BIOLOGICALLY )

ACTIVE DIMERIZED )

POLYPEPTIDE FUSIONS )

Examiner: C. Kaufman

Group Art Unit: 1646

TERMINAL DISCLAIMER

04/12/1999 HHORTON

00000004 201430 00000400

01 FC:148

110.00 CH

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Petitioner, ZymoGenetics, Inc., is the owner of 100 percent interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 5,750,375, U.S. Patent No. 5,155,027, and/or U.S. Patent No. 5,843,725. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on U.S.

Andrzej Z. Sledziewski  
Serial No. 08/980,400  
Page 2

Patent No. 5,750,375, U.S. Patent No. 5,155,027 and/or U.S. Patent No. 5,843,725 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as deemed in 35 U.S.C. 154 to 156 and 173 of any patent granted on U.S. Patent No. 5,750,375, U.S. Patent No. 5,155,027, and U.S. Patent No. 5,843,725, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned (whose title is supplied below) is empowered to act on behalf of the organization. Unless this Terminal Disclaimer is signed by an attorney of record, a Certificate Under 37 CFR § 3.73(b) is forwarded herewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may

Andrzej Z. Sledziewski  
Serial No. 08/980,400  
Page 3

jeopardize the validity of the application or any patent issued thereon.

Date: 3/28/99

By: 

Jeffrey J. King  
Reg. No. 38,515  
Attorney for Petitioner

i:\13952\53\2-1TERM.DIS